KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
1/9
08:02 am
kalv
Medium
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
1/8
04:27 pm
kalv
Medium
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
1/8
04:05 pm
kalv
Medium
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
1/6
08:00 am
kalv
Low
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
12/22
06:00 am
kalv
Low
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
11/10/2025
04:30 pm
kalv
5.3%
BEAT
9/11/2025
07:00 am
kalv
-9.4%
MISS
3/12/2025
07:00 am
kalv
-2.0%
MISS
3/12/2025
07:00 am
kalv
-2.0%
MISS
1/9
04:52 am
Maintains
Buy
Buy
Needham
Medium
-7.3%
1/9
04:52 am
Maintains
Buy
Buy
Needham
Medium
-7.3%
1/6
05:52 am
Maintains
Buy
Buy
Needham
Low
-0.1%
1/6
05:52 am
Maintains
Buy
Buy
Needham
Low
-0.1%
12/4
08:05 am
Reiterates
Buy
Buy
Needham & Company LLC
High
11.8%
1/13
06:04 pm
kalv
Low
Form SCHEDULE 13G/A KalVista Pharmaceuticals Filed by: Point72 Asset Management, L.P.
1/12
06:34 pm
kalv
Medium
Form SCHEDULE 13G KalVista Pharmaceuticals Filed by: Point72 Asset Management, L.P.
1/8
04:47 pm
kalv
Medium
Form 8-K KalVista Pharmaceuticals For: Jan 08
12/30
04:29 pm
kalv
Low
Form SCHEDULE 13G/A KalVista Pharmaceuticals Filed by: MILLENNIUM MANAGEMENT LLC
12/9
06:16 pm
kalv
Medium
Form 4 KalVista Pharmaceuticals For: Dec 06 Filed by: Palleiko Benjamin L
Show more
Top News Gainers
9/9 Q1/2019 7/31/2019 EPS -0.420 ZacksConsensus -0.610 ActVsEst 0.190 - Beat 9.9%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
Top News Decliners
3/10 Form 10-Q KalVista Pharmaceuticals For: Jan 31 -14.8%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3